04 June 2026
Dry eye disease is no longer a niche concern; it is one of the most common and rapidly growing challenges in modern eye care. From increasing digital device use to environmental factors and an ageing population, practitioners are seeing more patients presenting with symptoms such as irritation, fluctuating vision, redness and discomfort. Yet despite its prevalence, dry eye remains underdiagnosed, with only 20% of patients following the appropriate therapeutic management plan.
Today, forward-thinking practices are recognising that effective dry eye management is not only a clinical necessity but also a significant opportunity to improve patient satisfaction, loyalty and practice growth. With the right tools and approach, dry eye care can move from reactive symptom relief to proactive, measurable management. That’s where the Espansione portfolio, available through Essilor Instruments, is transforming the landscape.
Understanding the challenge
Dry eye disease is complex, yet in many cases, it is linked to meibomian gland dysfunction (MGD). Blocked or compromised glands fail to deliver the lipid layer needed to stabilise the tear film and without this protective layer, tears evaporate quickly, leaving patients in a cycle of irritation and inflammation.
Traditional approaches fail to address the root cause, meaning patients may experience temporary relief, but symptoms frequently persist or worsen over time. This creates frustration for both patients and practitioners, and highlights the need for more targeted, clinically effective solutions.
From diagnosis to management
Effective dry eye management starts with an accurate diagnosis. By identifying the underlying causes, practitioners are able to tailor plans that are specific to each patient.
Espansione’s product portfolio focuses on addressing MGD, through clinically proven, dual action light therapy for the management of dry eye disease and other ocular surface conditions. Supporting gland function and improving lipid secretion, helping restore the tear film’s natural balance.
This proactive approach not only alleviates symptoms but also helps to break the cycle, offering patients long-term relief, not just short-term fixes.
Eye-light®, Espansione’s flagship solution, combines Optimal Power Energy™ Intense Pulsed Light (OPE™ IPL) with Light Modulation™ Low-level Light Therapy (LM™ LLLT), to deliver targeted, condition-specific management for ocular surface diseases (OSD).
OPE™ IPL and LM™ LLLT jointly leveraged on eye-light® have been shown to deliver greater improvements in tear film quality and patient symptoms1 than competing IPL-only solutions, setting a new standard in light-based therapy.
Meibomask®, considered the best professional solution, leverages the benefits of LM™ LLLT technology, treating most ocular surface diseases and My-Mask® is the lightweight and portable solution offering a convenient and powerful solution wherever needed.
Practices that embrace dedicated dry eye solutions can differentiate themselves in a competitive market
A strategic opportunity for practices
Beyond the clinical benefits, dry eye management represents a significant growth opportunity. As awareness of dry eye disease increases, so too does demand for effective solutions. Practices that embrace dedicated dry eye solutions can differentiate themselves in a competitive market.
Espansione, available through Essilor Instruments, provides not just technology but a complete ecosystem from implementation, scale and optimisation of a dry eye management solution. With the right training, tools and support, practitioners can confidently introduce new revenue streams while elevating the standard of care.
Move beyond basic symptom management and embrace a more advanced, patient-focused approach. The result is better outcomes, stronger patient relationships, and a more resilient, future-ready practice.
Contact the team to discover more about the available solutions, and register your interest today.
References
- Castro C, Marques JH, Marta A, Baptista PM, José D, Sousa P, Menéres P, Barbosa I. Comparison of Light-Based Devices in the Treatment of Meibomian Gland Dysfunction. Cureus, 2023;15(7):e41386. doi:10.7759/cureus.41386.
